Safety of hormonal contraception for obese women

被引:8
作者
Rocha, Ana Luiza L. [1 ]
Campos, Rayana R. [1 ]
Miranda, Marina M. S. [1 ]
Raspante, Laio B. P. [1 ]
Carneiro, Marcia M. [1 ]
Vieira, Carolina S. [2 ,3 ]
Reis, Fernando M. [1 ]
机构
[1] Univ Fed Minas Gerais, Dept Gynecol & Obstet, Belo Horizonte, MG, Brazil
[2] Univ Sao Paulo, Med Sch Ribeirao Preto, Dept Gynecol & Obstet, Ribeirao Preto, Brazil
[3] Populat Council, 1230 York Ave, New York, NY 10021 USA
关键词
Hormonal contraception; drug safety; obesity; thrombosis; bariatric surgery; BODY-MASS INDEX; DEPOT-MEDROXYPROGESTERONE ACETATE; WEIGHT CHANGE; INTRAUTERINE SYSTEM; VENOUS THROMBOSIS; CHOICE PROJECT; RISK; PREGNANCY; HEALTH; USERS;
D O I
10.1080/14740338.2018.1389893
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Obese women have special safety requirements for contraceptive choice, but the evidence supporting such decision is dispersed and sometimes conflicting. Despite being effective, well tolerated and safe for most women, hormonal contraceptives are underused by obese women due to fear of contraceptive failure, weight gain and venous thrombosis. Areas covered: We performed a comprehensive literature search to identify studies about hormonal contraception in overweight and obese women, including safety concerns. We considered the safety of hormonal contraceptives for otherwise healthy obese women and for those with comorbidities such as hypertension, diabetes, vascular disease, or a history of deep venous thrombosis. Expert opinion: Over time there is no convincing evidence that obesity increases the risk of contraceptive failure. Hormonal contraceptive users may have a modest weight gain that is comparable to that of non-users. Current evidence supports the safe use of combined hormonal contraceptives by obese women after detailed clinical screening to exclude comorbidities that may contraindicate the use of estrogens. Progestin-only methods are generally safe, and long-acting reversible contraceptives hold the best combination of efficacy, safety and convenience for this group, although individualization is advisable.
引用
收藏
页码:1387 / 1393
页数:7
相关论文
共 69 条
  • [1] Pharmacologic Therapies in Women's Health Contraception and Menopause Treatment
    Allen, Caitlin
    Evans, Ginger
    Sutton, Eliza L.
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 2016, 100 (04) : 763 - +
  • [2] Combined hormonal contraception and the risk of venous thromboembolism: a guideline
    Pfeifer S.
    Butts S.
    Dumesic D.
    Fossum G.
    Gracia C.
    La Barbera A.
    Mersereau J.
    Odem R.
    Penzias A.
    Pisarska M.
    Rebar R.
    Reindollar R.
    Rosen M.
    Sandlow J.
    Sokol R.
    Vernon M.
    Widra E.
    [J]. FERTILITY AND STERILITY, 2017, 107 (01) : 43 - 51
  • [3] [Anonymous], 1998, Eur J Contracept Reprod Health Care, V3, P169
  • [4] [Anonymous], 2016, Obesity and Overweight, fact Sheet No. 311
  • [5] [Anonymous], BMJ
  • [6] [Anonymous], 2020, WHO Guidelines Approved by the Guidelines Review Committee
  • [7] Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods
    Bahamondes, Luis
    Bahamondes, M. Valeria
    Shulman, Lee P.
    [J]. HUMAN REPRODUCTION UPDATE, 2015, 21 (05) : 640 - 651
  • [8] Seventy-five microgram desogestrel minipill, a new perspective in estrogen-free contraception
    Benagiano, G
    Primiero, FM
    [J]. WOMEN'S HEALTH AND DISEASE: GYNECOLOGIC AND REPRODUCTIVE ISSUES, 2003, 997 : 163 - 173
  • [9] Does body mass index or weight perception affect contraceptive use?
    Bhuva, Kalpesh
    Kraschnewski, Jennifer L.
    Lehman, Erik B.
    Chuang, Cynthia H.
    [J]. CONTRACEPTION, 2017, 95 (01) : 59 - 64
  • [10] Preventing Unintended Pregnancy: The Contraceptive CHOICE Project in Review
    Birgisson, Natalia E.
    Zhao, Qiuhong
    Secura, Gina M.
    Madden, Tessa
    Peipert, Jeffrey F.
    [J]. JOURNAL OF WOMENS HEALTH, 2015, 24 (05) : 349 - 353